Phio Pharmaceuticals Corp. (PHIO)
USD 2.51
(-3.46%)
USD 2.51
(-3.46%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.74 Million | -12.12 Million | -11.85 Million | -8.8 Million | -8.64 Million | -7.52 Million |
| Net Income | -10.82 Million | -11.48 Million | -13.28 Million | -8.79 Million | -8.9 Million | -7.36 Million |
| Depreciation & Amortization | 184 Thousand | 193 Thousand | 75 Thousand | 72 Thousand | 67 Thousand | 81 Thousand |
| Deferred income taxes | 122 Thousand | -304 Thousand | -233 Thousand | - | - | - |
| Stock-based compensation | 303 Thousand | 414 Thousand | 480 Thousand | 136 Thousand | 300 Thousand | 282 Thousand |
| Change in working capital | -536 Thousand | -1.25 Million | 990 Thousand | -327 Thousand | -213 Thousand | -523 Thousand |
| Other non-cash items | 4000.00 | 304 Thousand | 117 Thousand | 111 Thousand | 109 Thousand | 405 Thousand |
| Investing Cash Flow | -5000.00 | -121 Thousand | -51 Thousand | -19 Thousand | -72 Thousand | -5000.00 |
| Investments in PPE | -5000.00 | -121 Thousand | -51 Thousand | -19 Thousand | -72 Thousand | -5000.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 7.41 Million | -26 Thousand | 21.72 Million | 16.13 Million | 772 Thousand | 18.82 Million |
| Debt repayment | - | - | - | -27 Thousand | -6000.00 | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -2000.00 | -28.00 | -1.00 | -15 Thousand | 1000.00 | 3000.00 |
| Common Stock Issuance | 7.45 Million | 2000.00 | 19.57 Million | 12.08 Million | 781 Thousand | 18.71 Million |
| Other Financing Activities | -37 Thousand | -28 Thousand | 2.14 Million | 8.17 Million | -3000.00 | 102 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -122 Thousand | 496 Thousand | -445 Thousand | -81 Thousand | 259 Thousand | 39 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -414 Thousand | -1.75 Million | 1.43 Million | -246 Thousand | -472 Thousand | -562 Thousand |
| Cash at beginning of period | 11.83 Million | 24.1 Million | 14.29 Million | 6.98 Million | 14.92 Million | 3.63 Million |
| Cash at end of period | 8.49 Million | 11.83 Million | 24.1 Million | 14.29 Million | 6.98 Million | 14.92 Million |
| Capital Expenditure | -5000.00 | -121 Thousand | -51 Thousand | -19 Thousand | -72 Thousand | -5000.00 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -3.34 Million | -12.27 Million | 9.81 Million | 7.31 Million | -7.94 Million | 11.29 Million |
| Free Cash Flow | -10.75 Million | -12.25 Million | -11.9 Million | -8.82 Million | -8.71 Million | -7.52 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.84 Million | -2.15 Million | -10.82 Million | -1.89 Million | -2.78 Million | -2.54 Million |
| Depreciation & Amortization | 1000.00 | 34 Thousand | 184 Thousand | 43 Thousand | 47 Thousand | 47 Thousand |
| Deferred income taxes | - | - | 122 Thousand | 389 Thousand | -651 Thousand | -18 Thousand |
| Stock-based compensation | 15 Thousand | 32 Thousand | 303 Thousand | 9000.00 | 89 Thousand | 94 Thousand |
| Change in working capital | 53 Thousand | 74 Thousand | -536 Thousand | -653 Thousand | -256 Thousand | -363 Thousand |
| Other non-cash items | 2000.00 | 439.99 Thousand | 4000.00 | -263 Thousand | 651 Thousand | 18 Thousand |
| Investing Cash Flow | - | - | -5000.00 | - | - | -5000.00 |
| Investments in PPE | - | - | -5000.00 | - | - | -5000.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | -4000.00 | 7.41 Million | 2.4 Million | - | 5.04 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -4000.00 | -2000.00 | -2000.00 | - | - |
| Common Stock Issuance | - | - | 7.45 Million | 2.4 Million | - | 5.04 Million |
| Other Financing Activities | - | -4000.00 | -37 Thousand | 1000.00 | - | 5048.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 15 Thousand | -337 Thousand | -122 Thousand | 484 Thousand | -468 Thousand | -261 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 38 Thousand | 411 Thousand | -414 Thousand | -1.13 Million | 212 Thousand | -102 Thousand |
| Cash at beginning of period | 6.47 Million | 8.49 Million | 11.83 Million | 8.45 Million | 11.35 Million | 9.08 Million |
| Cash at end of period | 4.69 Million | 6.47 Million | 8.49 Million | 8.49 Million | 8.45 Million | 11.35 Million |
| Capital Expenditure | - | - | -5000.00 | - | - | -5000.00 |
| Effect of forex changes on cash | - | - | - | 2.29 Million | - | -2.29 Million |
| Net cash flow / Change in cash | -1.77 Million | -2.01 Million | -3.34 Million | 33 Thousand | -2.9 Million | 2.27 Million |
| Free Cash Flow | -1.77 Million | -2.01 Million | -10.75 Million | -2.37 Million | -2.9 Million | -2.77 Million |
2145
PNDORA
ACML
NXPL
GSC
0212